New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More

Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer

By Maham Fatima | October 13, 2025, 9:28 AM

Natera Inc. (NASDAQ:NTRA) is one of the best growth stocks to buy now. On September 30, Natera announced the publication of a validation study for its personalized molecular residual disease test, Signatera, in the Journal of Clinical Oncology – Precision Oncology/JCO PO. The peer-reviewed manuscript features results from the largest-ever ctDNA study in testicular cancer and showed that Signatera outperformed standard-of-care serum tumor markers/STMs in prognostic evaluation.

The multicenter, retrospective study evaluated circulating tumor DNA/ctDNA as a prognostic biomarker for patients with germ cell tumors/GCTs, specifically testicular cancer, which accounts for ~95% of all GCTs and is the most common malignancy in men aged 15-35. The study analyzed 324 plasma samples from 74 patients with testicular cancer across stages I-III.

Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer

Signatera was used to assess ctDNA levels before, during, and after treatment to determine its association with event-free survival. Testicular cancer management is often complicated by the limited utility of conventional STMs, which can lead to unnecessary chemotherapy. Findings showed that Signatera-positivity was significantly associated with shorter EFS, highlighting its unique value to reliably detect molecular residual disease and predict clinical outcomes.

Natera Inc. (NASDAQ:NTRA) is a diagnostics company that provides molecular testing services worldwide. It serves independent laboratories, national & regional reference laboratories, medical centers & physician practices, research laboratories, and pharmaceutical companies.

While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

Mentioned In This Article

Latest News